S
Suzanne Swann
Researcher at GlaxoSmithKline
Publications - 18
Citations - 4854
Suzanne Swann is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Dabrafenib & Trametinib. The author has an hindex of 9, co-authored 18 publications receiving 4350 citations. Previous affiliations of Suzanne Swann include Novartis & CSL Behring.
Papers
More filters
Journal ArticleDOI
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild,Jean-Jacques Grob,Lev V. Demidov,Thomas Jouary,Ralf Gutzmer,Michael Millward,Piotr Rutkowski,Christian U. Blank,Wilson H. Miller,Eckhart Kaempgen,Salvador Martín-Algarra,Boguslawa Karaszewska,Cornelia Mauch,Vanna Chiarion-Sileni,Anne-Marie Martin,Suzanne Swann,Patricia Haney,Beloo Mirakhur,Mary E. Guckert,Vicki L. Goodman,Paul B. Chapman +20 more
TL;DR: Dabrafenib significantly improved progression-free survival compared with dacarbazine, and skin-related toxic effects, fever, fatigue, arthralgia, and headache were uncommon in both groups.
Journal ArticleDOI
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long,Georgina V. Long,Daniil Stroyakovskiy,Helen Gogas,Evgeny Levchenko,Filippo de Braud,James Larkin,Claus Garbe,Thomas Jouary,Axel Hauschild,Jean-Jacques Grob,Vanna Chiarion-Sileni,Céleste Lebbé,Mario Mandalà,Michael Millward,Ana Arance,Igor Bondarenko,John B. A. G. Haanen,Johan Hansson,Jochen Utikal,Jochen Utikal,Virginia Ferraresi,Nadezhda Kovalenko,Peter Mohr,Volodymr Probachai,Dirk Schadendorf,Paul Nathan,Caroline Robert,Caroline Robert,Antoni Ribas,Douglas J Demarini,Jhangir G. Irani,Suzanne Swann,Jeffrey J. Legos,Fan Jin,Bijoyesh Mookerjee,Keith T. Flaherty +36 more
TL;DR: The improvement in overall survival establishes the combination of dabrafenib and trametinib as the standard targeted treatment for BRAF Val600 mutation-positive melanoma.
Journal ArticleDOI
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long,Uwe Trefzer,Michael A. Davies,Richard F. Kefford,Paolo A. Ascierto,Paul B. Chapman,Igor Puzanov,Axel Hauschild,Caroline Robert,Alain Algazi,Laurent Mortier,Hussein Tawbi,Tabea Wilhelm,Lisa Zimmer,Julie Switzky,Suzanne Swann,Anne-Marie Martin,Mary E. Guckert,Vicki L. Goodman,Michael R. W. Streit,John M. Kirkwood,Dirk Schadendorf +21 more
TL;DR: Dabrafenib has activity and an acceptable safety profile in patients with Val600Glu BRAF-mutant melanoma and brain metastases irrespective of whether they are untreated or have been previously treated but have progressed.
Journal ArticleDOI
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial
Alexander M. Menzies,Michelle T. Ashworth,Suzanne Swann,Richard F. Kefford,Keith T. Flaherty,J.S. Weber,J. R. Infante,Kevin B. Kim,Rene Gonzalez,Omid Hamid,Lynn M. Schuchter,Jonathan Cebon,J. A. Sosman,Shonda M Little,Peng Sun,Gursel Aktan,Daniele Ouellet,Fan Jin,Georgina V. Long,Adil Daud +19 more
TL;DR: Pyrexia is a frequent and recurrent toxicity with CombiDT treatment, and dabrafenib and metabolite exposure may contribute to the etiology of pyrexia.
Journal ArticleDOI
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine
J.-J. Grob,Mayur M. Amonkar,Salvador Martín-Algarra,Lev V. Demidov,Vicki L. Goodman,Kelly M. Grotzinger,Patricia Haney,E. Kämpgen,Boguslawa Karaszewska,Cornelia Mauch,Wilson H. Miller,Michael Millward,Beloo Mirakhur,Piotr Rutkowski,Vanna Chiarion-Sileni,Suzanne Swann,Axel Hauschild +16 more
TL;DR: This first reported QoL analysis for a BRAF inhibitor in metastatic melanoma demonstrates that the high tumor response rates and PFS superiority of dabrafenib over DTIC is not only a theoretical advantage, but also transforms in a rapid functional and symptomatic benefit for the patient.